Cantor Fitzgerald lowered the firm’s price target on Pharvaris (PHVS) to $25 from $28 and keeps an Overweight rating on the shares. Pharvaris reported Q1 earnings and reiterated Phase 3 study readouts for on-demand treatment RAPIDe-3 in the first quarter of 2026, with target enrollment of 120 patients reached in March, and prophylactic treatment CHAPTER-3 in the second half of 2026, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
- Pharvaris reports Q1 EPS EUR (0.85) vs. EUR (0.52) last year
- Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
- Pharvaris initiated with an Overweight at Cantor Fitzgerald
- Pharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial Position